Literature DB >> 29094803

Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis.

Yan Liu1,2, Min Zhu2, Jing Geng3, Chengjun Ban2, Shu Zhang2, Wenhui Chen3, Yanhong Ren3, Xuan He3, Wang Chen3, Huaping Dai2,3.   

Abstract

OBJECTIVE: To investigate the incidence and risk factors of lung cancer in patients with idiopathic pulmonary fibrosis (IPF), and to learn the clinical, imaging and pathological features and of lung cancer in IPF.
METHODS: The study population included consecutive 268 IPF patients. Of them, 46 patients had pathologically or cytologically proven lung cancer. The demographic, clinical, HRCT and pathological features in patients with IPF and lung cancer were analysed and compared with the patients with IPF alone.
RESULTS: Of 268 IPF patients, 46 patients were diagnosed as IPF with lung cancer, accounted for 17.16%. 45.65% were adenocarcinoma. Lung cancer located mostly in the peripheral area and lower lobes of lungs consistent with IPF affected area. Old age and heavy smoking were risk factors of lung cancer developing in IPF. Chest pain and haemoptysis were more frequent in IPF patients with lung cancer than without lung cancer (P = .000). Nodular or mass shadows were found only in IPF patients with lung cancer (P = .000). The levels of CEA and CA125 in IPF patients were much higher in IPF patients with lung cancer (P ≤ .001). The median survival time was 36.2 ± 22.7 months in IPF patients, longer than 6.9 ± 3.3 months in IPF patients with lung cancer (P < .001).
CONCLUSIONS: Lung cancer frequently develops in patients with IPF, which is mainly adenocarcinoma, located in IPF affected area. Chest pain and haemoptysis are potential indicative of lung cancer developing in patients with IPF as atypical nodes or masses located in the peripheral areas and lower lobes on chest HRCT.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical features; idiopathic pulmonary fibrosis; lung cancer

Mesh:

Year:  2017        PMID: 29094803     DOI: 10.1111/crj.12732

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

1.  [Surgical Treatment of Lung Cancer Combined with Interstitial Lung Disease].

Authors:  Chuan Huang; Chao Ma; Qingjun Wu; Peng Jiao; Yaoguang Sun; Wenxin Tian; Hanbo Yu; Wen Huang; Yongzhong Wang; Hongfeng Tong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-05-20

2.  Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

Authors:  AliReza JafariNezhad; Mohammad Hossein YektaKooshali
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

3.  Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.

Authors:  Nobuyuki Koyama; Yuki Iwai; Yoshiaki Nagai; Kazutetsu Aoshiba; Hiroyuki Nakamura
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

Review 4.  Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review.

Authors:  Giulia Cassone; Marco Sebastiani; Caterina Vacchi; Gian Luca Erre; Carlo Salvarani; Andreina Manfredi
Journal:  Drugs Context       Date:  2021-01-15

5.  Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study.

Authors:  Bingbing Xie; Yanhong Ren; Jing Geng; Xuan He; Chengjun Ban; Shiyao Wang; Dingyuan Jiang; Sa Luo; Qihang Chen; Min Liu; Ruie Feng; Ling Zhao; Huaping Dai; Chen Wang
Journal:  BMJ Open       Date:  2020-11-11       Impact factor: 2.692

6.  [Research Progress in the Pathogenesis of Idiopathic Pulmonary Fibrosis with Lung Cancer].

Authors:  Chunhui Liu; Yuanbing He
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.